Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.56 |
| ▸ | ERBB2 | P04626 | 12/20 | 0.56 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.52 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.52 |
| ▸ | ROS1 | P08922 | 1/20 | 0.52 |
| ▸ | FLT3 | P36888 | 1/20 | 0.52 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.52 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.52 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.52 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimethylamine SCHEMBL6773331 | 0.86 | EGFR (0.60) | EGFRERBB2AURKBCHEK2ROS1 | |
| SCHEMBL6767933 | 0.84 | EGFR (0.60) | EGFRERBB2AURKBCHEK2ROS1 | |
| Dimethylamine SCHEMBL6767938 | 0.83 | EGFR (0.63) | EGFRERBB2AURKBCHEK2ROS1 | |
| SCHEMBL6773330 | 0.83 | EGFR (0.57) | EGFRERBB2AURKBCHEK2ROS1 | |
| SCHEMBL6767429 | 0.82 | EGFR (0.56) | EGFRERBB2AURKBCHEK2ROS1 | |
| SCHEMBL7912128 | 0.82 | ERBB2 (0.53) | EGFRERBB2AURKBCHEK2ROS1 | |
| SCHEMBL6766833 | 0.80 | ERBB2 (0.68) | EGFRERBB2 | |
| SCHEMBL6766845 | 0.79 | EGFR (0.55) | EGFRERBB2AURKBCHEK2ROS1 | |
| SCHEMBL7912134 | 0.78 | ERBB2 (0.52) | EGFRERBB2AURKBCHEK2ROS1 | |
| Dimethylamine SCHEMBL6764125 | 0.76 | EGFR (0.63) | EGFRERBB2AURKBCHEK2ROS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6828320-B2 | Enzyme inhibitors; anticancer agents | SMITHKLINE BEECHAM CORPORATION | 2004-12-07 | — | — | US | disclosed |
| US-20020147214-A1 | Heterocyclic compounds | NOVARTIS AG (CH) | 2002-10-10 | — | — | US | disclosed |
| US-6391874-B1 | ANTICARCINOGENIC AGENTS; SKIN DISORDERS | SMITHKLINE BEECHAM CORPORATION | 2002-05-21 | — | — | US | disclosed |
| EP-0912559-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1999-05-06 | — | — | EP | disclosed |
| WO-1998002434-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1998-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147214-A1 | Heterocyclic compounds | BRAF, ABL1, CSK | EGFR 354/4885ERBB2 35/4885AURKB 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.